|1.||Ulukaya, Engin: 10 articles (09/2015 - 10/2011)|
|2.||Yilmaz, Veysel T: 8 articles (02/2015 - 10/2011)|
|3.||Ari, Ferda: 7 articles (09/2015 - 10/2011)|
|4.||Feilzer, Albert J: 5 articles (05/2015 - 01/2008)|
|5.||Brantley, W A: 5 articles (10/2010 - 04/2002)|
|6.||Gambino, Dinorah: 4 articles (08/2015 - 06/2006)|
|7.||Kleverlaan, Cornelis J: 4 articles (05/2015 - 01/2008)|
|8.||Muris, Joris: 4 articles (05/2015 - 01/2008)|
|9.||Rustemeyer, Thomas: 4 articles (05/2015 - 01/2008)|
|10.||Divsalar, Adeleh: 4 articles (11/2014 - 09/2010)|
01/01/2008 - "Allergic reactions to palladium are rarely diagnosed with patch testing, even when positive results would be expected. "
01/01/2014 - "NKG2D⁺ IFN-γ⁺ CD8⁺ T cells are responsible for palladium allergy."
12/01/2012 - "As palladium allergy is an issue of growing interest, the diagnostic potential of Th2 parameters for palladium sensitization was investigated. "
08/01/2012 - "Exposure to palladium (Pd) may lead to clinical allergic reactions. "
07/01/2011 - "Palladium allergy prevalence is underestimated because of an inadequate test allergen."
|2.||Prostatic Neoplasms (Prostate Cancer)
03/01/2004 - "High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds."
02/01/2004 - "Palladium 103 is a radionuclide used in brachytherapy sources for the treatment of prostate cancers and also for other medical applications. "
12/01/2002 - "A total of 128 patients with prostate cancer underwent 3-D conformal radiation therapy (median dose 70.2 Gy. to the planning target volume) and 60 underwent palladium transperineal prostate brachytherapy (median dose 90 or 115 Gy. to 80% of the prostate with or without external nonconformal beam radiation therapy. "
06/01/2000 - "Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer."
01/01/2013 - "In this study, we screened the effect of a novel palladium-based anticancer agent (Pd complex) against six different prostate cancer cell lines, and primary cultures from seven Gleason 6/7 prostate cancer, three Gleason 8/9 prostate cancer and four benign prostate hyperplasia patient samples, as well as cancer stem cells selected from primary cultures. "
04/01/1996 - "Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study."
07/15/1996 - "To summarize biochemical failure rates and morbidity of external beam irradiation (EBRT) combined with palladium (103Pd) boost for clinically localized high-risk prostate carcinoma. "
01/01/2013 - "Among all the studied palladium(II) complexes, the [Pd(TSC(3))2] (8) complex exhibited high antitumor activity on the DU145 prostate carcinoma and K562 chronic myelogenous leukemia cells, with low values of the inhibitory concentration (0.01 and 0.02 μM, resp.). "
08/01/2015 - "Palladium interstitial implant in combination with external beam radiotherapy and chemotherapy for the definitive treatment of a female urethral carcinoma."
02/01/2007 - "The testing of the cytotoxic activity of the synthesized compounds together with their palladium analogues against human A2780 and A2780cisR epithelial ovarian carcinoma cells lines suggests that the compounds may be endowed with important antitumor properties since they show IC(50) values in a micromolar range similar to those of cisplatin. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2015 - "The purpose of this study was to design and synthesize Palladium nanoparticles (PdNPs) using an environmentally friendly approach and evaluate the in vitro efficacy of PdNPs in human ovarian cancer A2780 cells. "
01/01/2007 - "Low but significant activity of trans-palladium(II) complexes TH5, TH6 and TH7 against the ovarian cancer cell lines indicates that it is believed to be associated with the decrease in their reactivity due to the presence of two sterically hindered planaramine ligands."
10/01/2012 - "The present study deals with the synthesis, characterization, and activity against human ovarian cancer cell lines A2780, A2780(cisR), A2780(ZD0473R), and SKOV-3 of three trans-planaramine-palladium(II) complexes of the form trans-PdL(2)Cl(2), coded as EH1, EH3, and EH4, for which L = 2-methylpyridine, imidazole, and 1,2-α-imidazopyridine, respectively. "
05/01/2008 - "A deactivation model -- considering two different active sites (fresh and poisoning), pseudo-first order dependence on methane concentration and poisoning rate depending on sulphur concentration and fraction of non-poisoned palladium -- was used for modelling the deactivation behaviour."
05/01/2008 - "Sulphur poisoning of palladium catalysts used for methane combustion: effect of the support."
04/09/2008 - "Mechanisms of catalyst poisoning in palladium-catalyzed cyanation of haloarenes. "
09/01/1978 - "It was also demonstrated that the use of a barium-alumovanadium catalyst as a forecontact eliminated the effect of palladium catalyst poisoning and provided a high degree of convesrion during oxidation on this contact."
04/07/2012 - "Initial studies suggest the involvement of palladium nanoparticles, which has been further investigated using mercury-drop test and poisoning experiments."
|7.||DNA (Deoxyribonucleic Acid)
|9.||Adenocarcinoma of lung
|3.||Induced Hyperthermia (Thermotherapy)
|4.||Body Piercing (Piercing, Body)
|5.||Crowns (Crown, Dental)